SelectiveLXRinverseagonist.Exhibitsnosignificantactivityatothernuclearreceptorsatmaximallyeffectiveconcentration.InhibitstheWarburgeffectandlipogenesisbydown-regulationofLXR-mediatedgeneexpression.SelectivelyreducescellviABIlityandinducesapoptosisincancercelllinesinvitro.Suppresseshepaticsteatosisandinhibitsgrowthoftumorxenograftsinmice.
| M.Wt | 626.62 |
| Formula | C31H32BrNO4S2 |
| Storage | Storeat+4°C |
| Purity | ≥98%(HPLC) |
| CASNumber | 1613028-81-1 |
| PubChemID | 76073169 |
| InChIKey | FYQFEJFTCLKXTQ-UHFFFAOYSA-N |
| Smiles | CC1=CC(C)=CC(C)=C1S(N(CCC2=CC=CC(Br)=C2)CC(C=C3)=CC=C3C4=CC(S(=O)(C)=O)=CC=C4)(=O)=O |
Thetechnicaldataprovidedaboveisforguidanceonly.ForbatchspecificdatarefertotheCertificateofAnalysis.
AllTocrisproductsareintendedforlaboratoryresearchuseonly.
| Solvent | MaxConc.mg/mL | MaxConc.mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 12.53 | 20 |
Thefollowingdataisbasedontheproductmolecularweight626.62.Batchspecificmolecularweightsmayvaryfrombatchtobatchduetosolventofhydration,whichwillaffectthesolventvolumesrequiredtopreparestocksolutions.
| Concentration/SolventVolume/Mass | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1mM | 1.6mL | 7.98mL | 15.96mL |
| 5mM | 0.32mL | 1.6mL | 3.19mL |
| 10mM | 0.16mL | 0.8mL | 1.6mL |
| 50mM | 0.03mL | 0.16mL | 0.32mL |



